Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Finished Goods (2022 - 2025)

Historic Finished Goods for Fennec Pharmaceuticals (FENC) over the last 4 years, with Q3 2025 value amounting to $2.5 million.

  • Fennec Pharmaceuticals' Finished Goods rose 12017.78% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 12017.78%. This contributed to the annual value of $1.1 million for FY2024, which is 5083.49% down from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Finished Goods stood at $2.5 million, which was up 12017.78% from $2.2 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Finished Goods high stood at $2.5 million for Q3 2025, and its period low was $576000.0 during Q4 2022.
  • In the last 4 years, Fennec Pharmaceuticals' Finished Goods had a median value of $1.6 million in 2023 and averaged $1.6 million.
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 27430.56% in 2023, then plummeted by 5083.49% in 2024.
  • Quarter analysis of 4 years shows Fennec Pharmaceuticals' Finished Goods stood at $576000.0 in 2022, then surged by 274.31% to $2.2 million in 2023, then plummeted by 50.83% to $1.1 million in 2024, then soared by 133.68% to $2.5 million in 2025.
  • Its Finished Goods stands at $2.5 million for Q3 2025, versus $2.2 million for Q2 2025 and $1.4 million for Q1 2025.